Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

Dasatinib was approved at 100 mg once daily for imatinib‐resistant or ‐intolerant patients with chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180‐034 (NCT00123474) study. Here we present the final 7‐year analysis of this pivotal study, the longest follow‐up to da...

Full description

Bibliographic Details
Main Authors:	Shah, Neil P., Rousselot, Philippe, Schiffer, Charles, Rea, Delphine, Cortes, Jorge E., Milone, Jorge, Mohamed, Hesham, Healey, Diane, Kantarjian, Hagop, Hochhaus, Andreas, Saglio, Giuseppe
Format:	Online
Language:	English
Published:	John Wiley and Sons Inc. 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094534/

Similar Items

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
by: Oliver Ottmann, et al.
Published: (2018-09-01)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
by: Hochhaus, Andreas, et al.
Published: (2013)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
by: Ramchandren, Radhakrishnan, et al.
Published: (2009)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
by: Schiffer, Charles A., et al.
Published: (2016)

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
by: Hughes, T P, et al.
Published: (2015)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
by: Brümmendorf, Tim H., et al.
Published: (2015)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
by: Conchon, Monika, et al.
Published: (2011)

Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease
by: Sánchez-Ortega, Isabel, et al.
Published: (2016)

Suboptimal Responses in Chronic Myeloid Leukemia
by: Jabbour, Elias, et al.
Published: (2012)

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
by: Wang, Xiaoning, et al.
Published: (2013)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
by: Gambacorti-Passerini, Carlo, et al.
Published: (2014)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
by: Gambacorti‐Passerini, Carlo, et al.
Published: (2015)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
by: Gambacorti-Passerini, Carlo, et al.
Published: (2014)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
by: Zhu, Yu, et al.
Published: (2016)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
by: Uz, B., et al.
Published: (2011)

The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis
by: Mealing, Stuart, et al.
Published: (2013)

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
by: Halbach, Sebastian, et al.
Published: (2013)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Published: (2014)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
by: Kim, Yeo-Kyeoung, et al.
Published: (2014)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
by: Obr, Adam, et al.
Published: (2014)

Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells
by: Liu, Juan, et al.
Published: (2016)

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
by: Jelinek, Jaroslav, et al.
Published: (2011)

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
by: Chuah, Charles T., et al.
Published: (2014)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
by: Santoleri, Fiorenzo, et al.
Published: (2013)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
by: Lima, Lisa M, et al.
Published: (2010)

Systematic review of dasatinib in chronic myeloid leukemia
by: Breccia, Massimo, et al.
Published: (2013)

The role of dasatinib in the management of chronic myeloid leukemia
by: Chen, Runzhe, et al.
Published: (2015)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
by: Martinelli, Giovanni, et al.
Published: (2007)

NSK high strength BMPC bearings are &#034pumping up reliability&#034 in arduous petrochemical processing plants
Published: (2002)

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
by: Hochhaus, A, et al.
Published: (2016)

Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
by: Sigl, M, et al.
Published: (2013)

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells
by: Shi, Ping, et al.
Published: (2010)

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
by: Sasaki, Koji, et al.
Published: (2015)

PW03-034 – How to classify autoinflammatory diseases?
by: Grateau, G, et al.
Published: (2013)

P034. Technostress and primary headache: psychosocial risk
by: Pucci, Ennio, et al.
Published: (2015)

Imatinib in Chronic Myeloid Leukemia: an Overview
by: Sacha, Tomasz
Published: (2014)

O034. Type of pain and onabotulinumtoxin-A in chronic migraine: four years of follow-up
by: Cesaretti, Chiara, et al.
Published: (2015)

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
by: Haslam, Sonya
Published: (2005)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
by: Keskin, Dilek, et al.
Published: (2016)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
by: Hong, Ji Hyung, et al.
Published: (2015)